Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | KAT7 | O95251 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412062 | 0.92 | USP30 (0.54) | USP30PARP1KRASTRPV3SETD7 | |
| SCHEMBL4410437 | 0.90 | GPR119 (0.44) | USP30PARP1TRPV3SETD7KAT7 | |
| SCHEMBL4411290 | 0.89 | USP30 (0.46) | USP30PARP1TRPV3KAT7GPR119 | |
| SCHEMBL4409895 | 0.89 | KAT7 (0.44) | USP30PARP1TRPV3SETD7KAT7 | |
| SCHEMBL4410912 | 0.87 | MCL1 (0.42) | PARP1KAT7GPR119NR1H2NR1H3 | |
| SCHEMBL4417382 | 0.87 | CPS1 (0.48) | PARP1 | |
| SCHEMBL24558215 | 0.87 | USP30 (0.41) | USP30PARP1TRPV3SETD7KAT7 | |
| SCHEMBL29046811 | 0.85 | USP30 (0.43) | USP30TRPV3SETD7KAT7DPP4 | |
| SCHEMBL24558073 | 0.85 | USP30 (0.43) | USP30TRPV3SETD7KAT7DPP4 | |
| SCHEMBL4407351 | 0.85 | GPR119 (0.43) | PARP1KAT7GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | USP30 4369/4885PARP1 2847/4885KRAS 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.